ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$130M
(+36%)
Cap. Flow
+$141M
Cap. Flow
% of AUM
28.38%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
90
Reduced
44
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 2 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$4.21M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$3.91M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$3.78M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Structure Therapeutics
GPCR
$1.14B
| $59.5K | 0.01% |
1,516
-984
| -39% | -$38.6K |
|
177
Organon & Co
OGN
$2.52B
| $51.8K | 0.01% |
2,500
-3,500
| -58% | -$72.5K |
|
178
Ultra Clean Holdings
UCTT
$1.08B
| $49K | 0.01% |
1,000
| – | – |
|
179
Kohl's
KSS
$1.84B
| $46K | 0.01% |
2,000
| – | – |
|
180
Neurogene
NGNE
$280M
| $45.6K | 0.01% |
1,253
+592
| +90% | +$21.5K |
|
181
CASI Pharmaceuticals
CASI
$35.3M
| $45.3K | 0.01% |
+8,240
| New | +$45.3K |
|
182
Evotec
EVO
$1.2B
| $45.1K | 0.01% |
9,400
+1,700
| +22% | +$8.16K |
|
183
89bio
ETNB
$1.28B
| $44.5K | 0.01% |
5,560
+2,500
| +82% | +$20K |
|
184
4D Molecular Therapeutics
FDMT
$309M
| $42K | 0.01% |
2,000
| – | – |
|
|
TVRD
185
Tvardi Therapeutics, Inc. Common Stock
TVRD
$285M
| $41.1K | 0.01% |
+4,430
| New | +$41.1K |
|
186
Vera Therapeutics
VERA
$1.4B
| $39K | 0.01% |
+1,079
| New | +$39K |
|
|
CBIO
187
Crescent Biopharma, Inc. Common Stock
CBIO
$190M
| $38K | 0.01% |
+1,350
| New | +$38K |
|
188
Pharvaris
PHVS
$1.41B
| $37.6K | 0.01% |
2,000
| – | – |
|
|
ZVSA
189
DELISTED
ZyVersa Therapeutics
ZVSA
| $36.1K | 0.01% |
+9,598
| New | +$36.1K |
|
190
Pyxis Oncology
PYXS
$99.8M
| $33.1K | 0.01% |
10,000
| – | – |
|
191
Regenxbio
RGNX
$498M
| $31.6K | 0.01% |
2,700
+200
| +8% | +$2.34K |
|
192
Ventyx Biosciences
VTYX
$185M
| $29.9K | 0.01% |
12,955
+7,955
| +159% | +$18.4K |
|
193
Novo Nordisk
NVO
$249B
| $28.5K | 0.01% |
200
+100
| +100% | +$14.3K |
|
194
Perrigo
PRGO
$3.2B
| $28.2K | 0.01% |
1,100
+300
| +38% | +$7.7K |
|
195
Amphastar Pharmaceuticals
AMPH
$1.36B
| $28K | 0.01% |
700
| – | – |
|
196
NCR Atleos
NATL
$2.93B
| $27K | 0.01% |
1,000
| – | – |
|
197
Exact Sciences
EXAS
$9.73B
| $25.4K | ﹤0.01% |
600
-1,100
| -65% | -$46.5K |
|
198
NCR Voyix
VYX
$1.74B
| $24.7K | ﹤0.01% |
2,000
| – | – |
|
199
Axsome Therapeutics
AXSM
$6.21B
| $24.2K | ﹤0.01% |
+300
| New | +$24.2K |
|
200
Celcuity
CELC
$2.31B
| $22.9K | ﹤0.01% |
+1,400
| New | +$22.9K |
|